Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Chemosphere ; 358: 142222, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38714249

RESUMO

In this study, neural networks and support vector regression (SVR) were employed to predict the degradation over three pharmaceutically active compounds (PhACs): Ibuprofen (IBP), diclofenac (DCF), and caffeine (CAF) within a stirred reactor featuring a flotation cell with two non-concentric ultraviolet lamps. A total of 438 datapoints were collected from published works and distributed into 70% training and 30% test datasets while cross-validation was utilized to assess the training reliability. The models incorporated 15 input variables concerning reaction kinetics, molecular properties, hydrodynamic information, presence of radiation, and catalytic properties. It was observed that the Support Vector Regression (SVR) presented a poor performance as the ε hyperparameter ignored large error over low concentration levels. Meanwhile, the Artificial Neural Networks (ANN) model was able to provide rough estimations on the expected degradation of the pollutants without requiring information regarding reaction rate constants. The multi-objective optimization analysis suggested a leading role due to ozone kinetic for a rapid degradation of the contaminants and most of the results required intensification with hydrogen peroxide and Fenton process. Although both models were affected by accuracy limitations, this work provided a lightweight model to evaluate different Advanced Oxidation Processes (AOPs) by providing general information regarding the process operational conditions as well as know molecular and catalytic properties.


Assuntos
Diclofenaco , Peróxido de Hidrogênio , Ibuprofeno , Aprendizado de Máquina , Redes Neurais de Computação , Diclofenaco/química , Peróxido de Hidrogênio/química , Ibuprofeno/química , Cinética , Poluentes Químicos da Água/química , Poluentes Químicos da Água/análise , Cafeína/química , Oxirredução , Preparações Farmacêuticas/química , Preparações Farmacêuticas/análise , Ozônio/química , Máquina de Vetores de Suporte , Análise Custo-Benefício , Raios Ultravioleta , Catálise , Fotólise
3.
Clin. transl. oncol. (Print) ; 15(7): 503-508, jul. 2013. ilus
Artigo em Inglês | IBECS | ID: ibc-127462

RESUMO

The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs (AU)


Assuntos
Humanos , Adenocarcinoma/patologia , Carcinoma Pulmonar de Células não Pequenas/patologia , Neoplasias Pulmonares/patologia , Biomarcadores Tumorais/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/terapia , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/terapia , Diferenciação Celular , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/terapia , Terapia de Alvo Molecular
4.
Clin Transl Oncol ; 15(7): 503-8, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23359174

RESUMO

The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.


Assuntos
Adenocarcinoma/patologia , Biomarcadores Tumorais/metabolismo , Carcinoma Pulmonar de Células não Pequenas/patologia , Neoplasias Pulmonares/patologia , Adenocarcinoma/metabolismo , Adenocarcinoma/terapia , Adenocarcinoma de Pulmão , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/terapia , Diferenciação Celular , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/terapia , Terapia de Alvo Molecular
5.
Invest New Drugs ; 31(1): 14-9, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22669334

RESUMO

A high throughput screening for anticancer activity of FDA approved drugs identified mycophenolic acid (MPA), an inhibitor of inositol monophosphate dehydrogenase (IMPDH) as an active agent with an antiangiogenesis mode of action. Exposure of pancreatic cancer cell lines to MPA resulted in growth inhibition and reduced the expression of VEGF that was reversed by supplementing the media with guanosine supporting and IMPDH-dependant mechanism. In preclinical in vivo study, MPA showed a moderate inhibition of tumor growth in a panel of 6 human derived pancreatic cancer xenografts but reduced the expression of VEGF. To investigate the effects of MPA in human pancreatic cancer, a total of 12 patients with resectable pancreatic cancer (PDA) received increasing doses of mycophenolate mofetil (MMF) in cohorts of 6 patients each from 5-15 days prior to surgical resection. Treatment was well tolerated with one episode of grade 1 muscle pain, one episode of grade 2 lymphopenia (2 gr/day dose) and one episode of grade 2 elevantion in LFT (all in the 2 gr./day dose). Patients recovered from surgery uneventfully with no increased post-operative complications. Assessment of CD31, VEGF, and TUNEL in resected specimens compared to a non treated control of 6 patients showed no significant variations in any of the study endpoints. In conclusion, this study shows the feasibility of translating a preclinical observation to the clinical setting and to explore a drug mechanism of action in patients. MPA, however, did not show any hints of antiangiogenesis of anticancer clinical activity questioning if this agent should be further developed in PDA.


Assuntos
Carcinoma Ductal Pancreático/tratamento farmacológico , Imunossupressores/uso terapêutico , Ácido Micofenólico/análogos & derivados , Neoplasias Pancreáticas/tratamento farmacológico , Idoso , Animais , Carcinoma Ductal Pancreático/metabolismo , Carcinoma Ductal Pancreático/patologia , Linhagem Celular Tumoral , Feminino , Guanosina Trifosfato/metabolismo , Humanos , Imunossupressores/sangue , Imunossupressores/farmacologia , Masculino , Camundongos , Pessoa de Meia-Idade , Ácido Micofenólico/sangue , Ácido Micofenólico/farmacologia , Ácido Micofenólico/uso terapêutico , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patologia , Resultado do Tratamento , Carga Tumoral/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto
6.
Br J Cancer ; 107(2): 345-51, 2012 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-22713664

RESUMO

BACKGROUND: KRAS mutation testing is required to select patients with metastatic colorectal cancer (CRC) to receive anti-epidermal growth factor receptor antibodies, but the optimal KRAS mutation test method is uncertain. METHODS: We conducted a two-site comparison of two commercial KRAS mutation kits - the cobas KRAS Mutation Test and the Qiagen therascreen KRAS Kit - and Sanger sequencing. A panel of 120 CRC specimens was tested with all three methods. The agreement between the cobas test and each of the other methods was assessed. Specimens with discordant results were subjected to quantitative massively parallel pyrosequencing (MPP). DNA blends were tested to determine detection rates at 5% mutant alleles. RESULTS: Reproducibility of the cobas test between sites was 98%. Six mutations were detected by cobas that were not detected by Sanger, and five were confirmed by MPP. The cobas test detected eight mutations which were not detected by the therascreen test, and seven were confirmed by MPP. Detection rates with 5% mutant DNA blends were 100% for the cobas and therascreen tests and 19% for Sanger. CONCLUSION: The cobas test was reproducible between sites, and detected several mutations that were not detected by the therascreen test or Sanger. Sanger sequencing had poor sensitivity for low levels of mutation.


Assuntos
Neoplasias Colorretais/genética , Mutação , Proteínas Proto-Oncogênicas/genética , Proteínas ras/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Colorretais/patologia , Feminino , Formaldeído , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas Proto-Oncogênicas p21(ras) , Reprodutibilidade dos Testes , Análise de Sequência de DNA , Fixação de Tecidos
7.
J Pathol ; 214(3): 347-56, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17992665

RESUMO

The development of targeted therapies creates a need to discriminate tumours accurately by their histological and genetic characteristics. Here, we aim to identify gene expression profiles and single markers that recapitulate the pathological and genetic background of non-small cell lung cancer (NSCLC). We performed cDNA microarray analysis on a series of 69 NSCLCs, with known mutation status for important genes, and six normal lung tissues. Unsupervised cluster analysis segregated normal lungs from lung tumours and lung tumours according to their histopathology and the presence of EGFR mutations. Several transcripts were highly overexpressed (by approximately 20 times) in squamous cell carcinomas (SCCs) relative to adenocarcinomas (ACs) and confirmed by immunohistochemistry in an independent cohort of 75 lung tumours. Expression of 13 genes constituted the most prominent hallmarks of EGFR-mutant tumours, including increased levels of proline dehydrogenase (PRODH) and down-regulation of X-box binding protein 1 (XBP1). No genes were differentially expressed, with a fold change >or= 4 or

Assuntos
Carcinoma Pulmonar de Células não Pequenas/genética , Perfilação da Expressão Gênica , Marcadores Genéticos , Neoplasias Pulmonares/genética , Análise de Sequência com Séries de Oligonucleotídeos , Adenocarcinoma/genética , Carcinoma de Células Escamosas/genética , Estudos de Casos e Controles , Classe I de Fosfatidilinositol 3-Quinases , Análise por Conglomerados , Receptores ErbB/genética , Amplificação de Genes , Genes ras , Humanos , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Mutação , Fosfatidilinositol 3-Quinases/genética
8.
Cienc. ginecol ; 6(1): 24-26, ene. 2002. ilus
Artigo em Es | IBECS | ID: ibc-14246

RESUMO

Se presenta el caso de una gestante de 33 semanas con rotura prematura de membranas en el que se sospechó un prolapso de cordón gracias a las características de cardiotocograma basal que presentaba deceleraciones variables. (AU)


Assuntos
Adulto , Gravidez , Feminino , Humanos , Recém-Nascido , Cardiotocografia/métodos , Cordão Umbilical , Doenças Fetais/diagnóstico , Ruptura Prematura de Membranas Fetais/fisiopatologia , Prolapso , Cesárea
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...